Canada Markets close in 3 mins

PFE Sep 2022 40.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
8.40-1.63 (-16.25%)
As of 12:33PM EDT. Market open.
Full screen
Previous Close10.03
Open8.60
Bid8.30
Ask8.50
Strike40.00
Expire Date2022-09-16
Day's Range8.30 - 9.25
Contract RangeN/A
Volume171
Open Interest663
  • Zacks

    Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

    Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.

  • Reuters

    UPDATE 6-Plaintiff in first Zantac lawsuit set for trial drops case

    Tuesday's news came days after shares of GlaxoSmithKline Plc , Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac. Alexandra Walsh, an attorney for Bayer, said her client could not proceed for "personal health reasons" but had the right to refile his case within a year.

  • Reuters

    Plaintiff in first Zantac lawsuit set for trial drops case

    The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants. Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.